Compare Stocks

→ World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APTX Aptinyx	$0.10 +3.1%	$0.08	$0.01 ▼ $0.72	N/A	1.27	1.32 million shs	231,100 shs
BIVI BioVie	$0.49 -3.9%	$0.74	$0.45 ▼ $8.69	$19.52M	0.79	2.12 million shs	775,654 shs
CALA Calithera Biosciences	$0.02 -33.3%	$0.02	$0.01 ▼ $0.50	$97K	-0.17	877 shs	191 shs
MIST Milestone Pharmaceuticals	$1.59 -4.2%	$1.67	$1.33 ▼ $4.49	$84.51M	1.77	307,891 shs	251,681 shs
SIOX Sio Gene Therapies	$0.48 +1.7%	$0.46	$0.25 ▼ $0.50	N/A	1.14	N/A	40,400 shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APTX Aptinyx	0.00%	0.00%	0.00%	0.00%	-20.00%
BIVI BioVie	+2.77%	+7.21%	-10.71%	-46.38%	-92.86%
CALA Calithera Biosciences	0.00%	-27.50%	+45.00%	-3.33%	-27.50%
MIST Milestone Pharmaceuticals	-1.76%	-4.57%	-3.47%	+6.37%	-56.17%
SIOX Sio Gene Therapies	0.00%	0.00%	0.00%	+22.88%	+16.30%

These AI trades triggered this morning (545% return) (Ad)

If you think a market crash is possible in 2024, I don't know why you're not using this yet.

Click Here To Get Your Free Copy

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APTX Aptinyx	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BIVI BioVie	1.8235 of 5 stars	3.3	5.0	0.0	0.0	2.4	0.0	0.0
CALA Calithera Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MIST Milestone Pharmaceuticals	2.178 of 5 stars	3.4	5.0	0.0	0.0	0.6	2.5	0.0
SIOX Sio Gene Therapies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APTX Aptinyx	N/A	N/A	N/A	N/A
BIVI BioVie	2.50	Moderate Buy	$8.00	1,536.33% Upside
CALA Calithera Biosciences	N/A	N/A	N/A	N/A
MIST Milestone Pharmaceuticals	2.75	Moderate Buy	$10.75	576.10% Upside
SIOX Sio Gene Therapies	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest MIST, BIVI, SIOX, APTX, and CALA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/22/2024	MIST Milestone Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
3/5/2024	MIST Milestone Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$6.00 ➝ $5.00
2/26/2024	MIST Milestone Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00

(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APTX Aptinyx	$1M	N/A	N/A	N/A	$0.57 per share	N/A
BIVI BioVie	N/A	N/A	N/A	N/A	$0.42 per share	N/A
CALA Calithera Biosciences	$9.75M	0.01	N/A	N/A	($0.40) per share	-0.05
MIST Milestone Pharmaceuticals	$1M	84.51	N/A	N/A	$0.50 per share	3.18
SIOX Sio Gene Therapies	N/A	N/A	N/A	N/A	N/A	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APTX Aptinyx	-$64.85M	-$0.98	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BIVI BioVie	-$50.26M	-$1.17	N/A	∞	N/A	N/A	-332.18%	-137.85%	5/10/2024 (Estimated)
CALA Calithera Biosciences	-$39.65M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
MIST Milestone Pharmaceuticals	-$59.69M	-$1.39	N/A	N/A	N/A	N/A	-170.99%	-64.45%	5/9/2024 (Estimated)
SIOX Sio Gene Therapies	-$71.89M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest MIST, BIVI, SIOX, APTX, and CALA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/21/2024	Q4 2023	MIST Milestone Pharmaceuticals	-$0.30	-$0.32	-$0.02	-$0.32	N/A	N/A
2/12/2024	Q2 2024	BIVI BioVie	-$0.32	-$0.22	+$0.10	-$0.22	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APTX Aptinyx	N/A	N/A	N/A	N/A	N/A
BIVI BioVie	N/A	N/A	N/A	N/A	N/A
CALA Calithera Biosciences	N/A	N/A	N/A	N/A	N/A
MIST Milestone Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SIOX Sio Gene Therapies	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APTX Aptinyx	N/A	N/A	N/A
BIVI BioVie	N/A	1.47	1.47
CALA Calithera Biosciences	N/A	N/A	N/A
MIST Milestone Pharmaceuticals	2.97	10.11	10.11
SIOX Sio Gene Therapies	N/A	N/A	N/A

Ownership

Institutional Ownership

Company	Institutional Ownership
APTX Aptinyx	N/A
BIVI BioVie	4.59%
CALA Calithera Biosciences	N/A
MIST Milestone Pharmaceuticals	86.18%
SIOX Sio Gene Therapies	N/A

Insider Ownership

Company	Insider Ownership
APTX Aptinyx	10.97%
BIVI BioVie	4.80%
CALA Calithera Biosciences	6.60%
MIST Milestone Pharmaceuticals	10.40%
SIOX Sio Gene Therapies	3.40%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
APTX Aptinyx	12	N/A	N/A	Not Optionable
BIVI BioVie	18	39.92 million	38.01 million	Optionable
CALA Calithera Biosciences	8	4.87 million	4.55 million	Not Optionable
MIST Milestone Pharmaceuticals	47	53.15 million	47.62 million	Optionable
SIOX Sio Gene Therapies	12	N/A	N/A	No Data

MIST, BIVI, SIOX, APTX, and CALA Headlines

Source	Headline
	Gene therapy and the germline nature.com - April 22 at 11:05 AM
	Gene Therapy for Parkinson's Disease medscape.com - March 31 at 1:50 AM
	Sio Gene Therapies, Inc. to File for Dissolution and Declare an Initial Liquidating Distribution of $0.435 Per Share finance.yahoo.com - February 2 at 7:47 AM
	Sio Gene Therapies Inc SIOX morningstar.com - November 22 at 2:04 PM
	Two Promising Gene Therapy Stocks Tackling Eye Disease thestreet.com - November 1 at 5:29 PM
	Gene Therapy News and Research news-medical.net - October 28 at 10:40 AM
	Gene Therapy for Erectile Dysfunction medscape.com - October 23 at 7:00 PM
	In Mice, Gene Therapy Helps Restore Movement After Spinal Cord Injury siouxcityjournal.com - September 27 at 3:06 PM
	Retroviral Vectors for Gene Therapy medscape.com - September 18 at 4:21 PM
	Sio Gene Therapies (NASDAQ: AXGT) fool.com - July 19 at 2:34 AM
	Roivant in Talks to Sell Stomach Drug to Roche in Deal Valued at More Than $7 Billion finance.yahoo.com - July 13 at 7:44 PM
	Gene Therapy in a Patient with Sickle Cell Disease nejm.org - June 20 at 10:04 PM
	Gene Therapy for Rheumatoid Arthritis medscape.com - June 12 at 11:10 PM
	A gene therapy shot might keep cats from getting pregnant without being spayed sciencenews.org - June 12 at 6:10 PM
	A new gene therapy could be a game-changer for patients with severe anemia. The cost? $2.8 million. nbcnews.com - May 23 at 4:21 PM
	Sio Gene Therapies Announces Fiscal Third Quarter 2022 Financial Results finance.yahoo.com - February 14 at 8:17 AM
	SIOX Sio Gene Therapies Inc. seekingalpha.com - January 26 at 5:44 PM
	Sio Gene Therapies to dissolve after years of setbacks biopharmadive.com - December 15 at 2:28 PM
	Sio Gene Therapies Inc. Announces Board Approval of Plan of Complete Liquidation and Dissolution finance.yahoo.com - December 14 at 6:35 PM
	Following layoffs, gene therapy firm leaves Durham bizjournals.com - November 10 at 3:59 PM
	Sio Gene Therapies Announces Fiscal Second Quarter 2022 Financial Results finance.yahoo.com - November 10 at 7:26 AM
	Sio Gene Therapies (NASDAQ:SIOX) Will Have To Spend Its Cash Wisely finance.yahoo.com - October 31 at 1:26 PM
	Sio Gene Therapies Announces Fiscal First Quarter 2022 Financial Results finance.yahoo.com - August 11 at 5:41 PM
	Sio Gene Therapies Inc. (SIOX) uk.finance.yahoo.com - August 5 at 9:37 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

3 Value Stocks Too Small For Buffett’s Portfolio
March 28, 2024 12:16 PM
View 3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian benchmarks mostly climb despite worries about US economy
April 25, 2024 2:14 AM
View Stock market today: Asian benchmarks mostly climb despite worries about US economy
Foot Locker Builds Up Another Head of Steam; Gains Imminent
March 28, 2024 10:58 AM
View Foot Locker Builds Up Another Head of Steam; Gains Imminent
5 Stocks in the Current Bull Market with Upside to Come
April 5, 2024 10:14 AM
View 5 Stocks in the Current Bull Market with Upside to Come
ASML Fires Warning Shot For Tech Investors
April 17, 2024 9:05 AM
View ASML Fires Warning Shot For Tech Investors

All Headlines

Company Descriptions

Aptinyx

NASDAQ:APTX

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Its lead product candidate NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat opioid use disorder, or OUD; and in preclinical trial for the treatment of alcohol use disorder, or AUD. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.

BioVie

NASDAQ:BIVI

BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

Calithera Biosciences

NASDAQ:CALA

Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.

Milestone Pharmaceuticals

NASDAQ:MIST

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Sio Gene Therapies

NASDAQ:SIOX

Sio Gene Therapies Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical School to develop and commercialize gene therapy product candidates, including AXO-AAV-GM1 and AXO-AAV-GM. The company was formerly known as Axovant Gene Therapies Ltd. and changed its name to Sio Gene Therapies, Inc. in November 2020. Sio Gene Therapies, Inc. was incorporated in 2014 and is based in New York, New York.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial